Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Disrupted Micronuclei Cited as Potential Non-Small-Cell Lung Cancer Biomarkers

By BiotechDaily International staff writers
Posted on 16 Jul 2013
Cancer researchers have found that collapse of the nuclear membrane that surrounds micronuclei—bits of the genome that become detached during cell replication—may allow these damaged segments of DNA to reenter the cell's genetic material with possible cancer-causing consequences.

Investigators at the Salk Institute for Biological Sciences (La Jolla, CA, USA) worked with cultures of non-small-cell lung cancer (NSCLC) cells. They reported in the July 3, 2013, issue of the journal Cell that micronuclei, which were sometimes generated when these cells replicated, had reduced functioning compared to primary nuclei in the same cell, although the two compartments appeared to be structurally comparable. Over 60% of micronuclei were found to undergo an irreversible loss of compartmentalization during interphase due to collapse of their nuclear envelope.

The disruption of the micronuclei, which was induced by defects in nuclear lamina assembly, drastically reduced nuclear functions and had the potential to trigger massive DNA damage. Disruption of micronuclei was associated with chromatin compaction and invasion of endoplasmic reticulum (ER) tubules into the chromatin.

Disrupted micronuclei were detected in both major subtypes of NSCLC, suggesting that this feature could be a useful objective biomarker for genomic instability in solid tumors.

"Our study shows that more than 60% of micronuclei undergo catastrophic dysfunction in solid tumors such as NSCLC," said senior author Dr. Martin Hetzer, professor of molecular and cell biology at the Salk Institute for Biological Sciences. "We identified disrupted micronuclei in two major subtypes of human non-small-cell lung cancer, which suggests that they could be a valuable tool for cancer diagnosis."

Related Links:
Salk Institute for Biological Sciences



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.